Nirsevimab's RSV Protection Didn't Extend to Second Year

(MedPage Today) -- The monoclonal antibody nirsevimab (Beyfortus) consistently performed well against respiratory syncytial virus (RSV)-related hospitalization during infants' first year after receipt but without a benefit for other hospitalizations...